A recent press release reports, “Specialty diagnostics company Precipio, Inc., announced today an agreement with Israel-based artificial intelligence pathology platform company Nucleai who specializes in applying Machine Learning and Machine Vision algorithms to pathology domain. Nucleai’s experienced team has adapted artificial intelligence technology previously used for satellite image analysis to the detection of cancer using biopsy image analysis to distinguish between abnormal, potentially malignant cells and normal cells. Nucleai’s platform assists pathologists during their morphologic assessment of a biopsy with a pre-scan of slides to identify areas of potential abnormality, reducing scanning time and improving accuracy by allowing the pathologist to focus on areas of interest.”
The release goes on, “The morphologic assessment is arguably the most critical part of the diagnostic process and the stage where the training, experience and expertise of the pathologist is key to locating and identifying abnormal, malignant cells. The platform’s benefit is not a replacement for the expertise of the diagnosing pathologist; but rather an enhancement that assist pathologists in delivering a more accurate diagnosis and higher throughput of cases, potentially saving resources and lives through improved cancer care. Nucleai has initially developed solutions for prostate, breast and gastrointestinal related diseases. The partnership with Precipio, with its focus on Hematopathology, will allow Nucleai to expand its product offering.
Read more at Nasdaq.
Photo credit: Nucleai